Cargando…
Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer
SIMPLE SUMMARY: Targeted radionuclide therapy (TRT) delivers cancer-selective radiopharmaceuticals to eradicate cancer cells while sparing healthy tissue. The recent development of combinatory treatments is a growing research field in nuclear medicine to enhance cancer cytotoxicity of TRT. Among pro...
Autores principales: | Grzmil, Michal, Wiesmann, Fabius, Schibli, Roger, Behe, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817840/ https://www.ncbi.nlm.nih.gov/pubmed/36612012 http://dx.doi.org/10.3390/cancers15010017 |
Ejemplares similares
-
Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [(177)Lu]Lu-PP-F11N
por: Grzmil, Michal, et al.
Publicado: (2020) -
Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020) -
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)
por: Grzmil, Michal, et al.
Publicado: (2022) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016) -
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
por: Feldman, Morris E, et al.
Publicado: (2009)